Distribuzione geografica
Continente #
NA - Nord America 66.656
EU - Europa 3.166
AS - Asia 1.209
Continente sconosciuto - Info sul continente non disponibili 24
SA - Sud America 21
OC - Oceania 18
AF - Africa 12
Totale 71.106
Nazione #
US - Stati Uniti d'America 66.626
IE - Irlanda 790
UA - Ucraina 660
CN - Cina 632
IT - Italia 540
KR - Corea 488
DE - Germania 432
GB - Regno Unito 207
FI - Finlandia 174
FR - Francia 122
SE - Svezia 68
PL - Polonia 45
BE - Belgio 37
RU - Federazione Russa 32
CA - Canada 29
EU - Europa 19
JP - Giappone 19
AU - Australia 17
NL - Olanda 16
IN - India 15
IR - Iran 10
BR - Brasile 8
EG - Egitto 7
ES - Italia 7
VN - Vietnam 7
HK - Hong Kong 6
CH - Svizzera 5
PE - Perù 5
CO - Colombia 4
HU - Ungheria 4
RO - Romania 4
SG - Singapore 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
AR - Argentina 3
AT - Austria 3
BD - Bangladesh 3
GR - Grecia 3
ID - Indonesia 3
MK - Macedonia 3
PK - Pakistan 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
IL - Israele 2
KZ - Kazakistan 2
NO - Norvegia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TR - Turchia 2
TW - Taiwan 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
CZ - Repubblica Ceca 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SC - Seychelles 1
SD - Sudan 1
Totale 71.106
Città #
Houston 21.910
Woodbridge 18.073
Wilmington 15.951
Fairfield 2.282
Ann Arbor 1.468
Ashburn 950
Seattle 889
Cambridge 827
Chandler 824
Dublin 731
Jacksonville 580
Dearborn 568
Medford 520
Lawrence 249
Beijing 230
Rome 230
Hangzhou 131
San Diego 114
Menlo Park 99
London 67
Milan 64
Creede 52
Center 51
Norwalk 40
Seoul 40
Kraków 39
Brussels 34
Zhengzhou 32
Nanjing 30
Hefei 29
Mountain View 28
Shanghai 27
Hackensack 26
Chicago 24
Engelhard 24
Redwood City 23
Helsinki 21
Guangzhou 20
Verona 20
Kunming 18
Toronto 18
Detroit 15
Nanchang 13
Indiana 10
Jinan 10
Billings 9
Boardman 9
Florence 9
Fuzhou 9
New York 8
Saint Petersburg 8
Washington 8
Chiswick 7
Monte Vista 7
Mülheim 7
Redmond 7
Tokyo 7
Torre Del Greco 7
Bologna 6
Dong Ket 6
New Bedfont 6
Phoenix 6
Changsha 5
Falls Church 5
Hebei 5
Lima 5
San Francisco 5
Shenyang 5
Simi Valley 5
Taiyuan 5
Victoria 5
Wuhan 5
Brescia 4
Budapest 4
La Veta 4
Ladenburg 4
Palo Alto 4
Paris 4
Siena 4
São Paulo 4
Urbana 4
Xian 4
Albano Laziale 3
Andong 3
Bari 3
Central 3
Chengdu 3
Clearwater 3
Islington 3
Kish 3
Latina 3
Los Angeles 3
Marseille 3
Melbourne 3
Mèze 3
Nürnberg 3
Pescorocchiano 3
Redditch 3
San Jose 3
Stony Brook 3
Totale 67.671
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.331
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.616
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.576
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.224
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.152
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 463
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 455
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 425
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 420
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 416
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 414
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 412
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 407
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 406
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 406
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 405
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 405
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 403
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 399
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 398
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 396
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 392
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 392
Panobinostat for the treatment of acute myelogenous leukemia 392
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 391
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 389
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 388
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 387
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 387
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 386
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 385
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 385
Small lymphocytic lymphoma in a patient with Fabry disease 384
Therapy related leukemias: susceptibility, prevention and treatment 384
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 384
Clonal evolution in therapy-related neoplasms 383
Mobilization and selection of CD34+ cells 382
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 381
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 381
Prevalence of obesity in young adults with acute lymphoblastic leukemia 380
New treatments for myelodysplastic syndromes 380
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 379
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 379
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 379
Hepato-splenic mycotic abscesses in patients with acute leukemia 379
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 378
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 378
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 378
Epigenetic changes in therapy-related MDS/AML 376
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 375
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 374
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 373
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 372
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 370
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 370
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 369
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 367
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 367
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 367
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 366
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 366
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 365
Why methylation is not a marker predictive of response to hypomethylating agents 364
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 364
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 363
Incidence and susceptibility to therapy-related myeloid neoplasms 362
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 362
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 362
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 362
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 360
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 359
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 359
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 358
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 358
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 357
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 357
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 357
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 355
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 355
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 354
Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker 354
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 353
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 353
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 350
Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan 349
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 349
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 348
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 348
Fanconi anemia gene variants in therapy-related myeloid neoplasms 348
Outcome of therapy-related myeloid neoplasms treated with azacitidine 348
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 347
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 347
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 345
Inhibition of hematopoiesis by competitive binding of transcription factor PU.1 345
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 343
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 343
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 343
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 342
Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms 342
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 341
Totale 43.475
Categoria #
all - tutte 110.744
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.744

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201918.126 0 0 0 818 615 1.339 1.305 7.317 1.253 1.747 1.973 1.759
2019/202018.772 1.808 1.314 1.207 1.871 1.657 1.998 1.784 1.761 1.816 1.408 1.087 1.061
2020/202110.722 1.251 1.127 1.149 1.220 1.371 1.087 1.354 1.072 279 266 439 107
2021/20222.462 118 289 124 61 77 209 128 148 166 142 262 738
2022/20232.845 336 174 135 271 181 689 555 123 210 23 83 65
2023/2024326 127 42 157 0 0 0 0 0 0 0 0 0
Totale 72.220